The company's focus is on two clinical assets: oncology and wound healing. Their lead product, tigilanol tiglate, is a small molecule administered intratumorally that has the potential to treat a range of solid tumors as a monotherapy or in combination with checkpoint inhibitor drugs. QBiotics applies a data-driven approach to discover plant-derived small molecule scaffolds for use in human and animal health. They have a proven track record of successfully partnering and commercializing their products, and are dedicated to improving lives through the discovery of transformational pharmaceuticals.